Hello to all! This summer proved again to be challenging, however, hope is everywhere for a brighter fall and winter of 2021. The resilience of our healthcare teams around the country has been incredible. I would like to thank everyone involved in Advances in Pulmonary Hypertension, who over the 20 months, have worked day and night to get the issues out during the pandemic. The guest editors, editorial board, authors and everyone at PHA have been truly phenomenal. Every issue and article published has been outstanding. Thank you and congratulations. All of these issues are state of the art resources that will be the backbone of each topic for years to come.

Our current issue is no different. The issue is focused on PH-ILD, a topic that has fascinated our field forever. This issue delves into the pathophysiology, etiology and management of this difficult disease state. Congratulations to all involved in this work which is so timely to our field.

In the first article of this issue, Drs. Farbod and Franck Rahaghi introduce the topic discussing the pathogenesis, identification, evaluation, and monitoring of PH-ILD. The authors reveal what is known about the clinical impact of PH in ILD. They move on from there to the actual evaluation and considerations in management of the disease.

In the next article, Drs. Denise Gabrielle Sese and Kristin Highland discuss the difficult topic of Connective Tissue Disease, Interstitial Lung Disease, and Pulmonary Hypertension (CTD PH-ILD). They review the differences (both in terms of severity and management) between CTD PH-ILD and PH-ILD. It is a topic that is so important for us all to recognize while caring for these patients.

In our third article, Dr. Eileen Harder and Dr. Aaron Waxman take us through the management strategies from the past, present and what we can look forward to in the future for PH-ILD. Discussions of therapies, transplant evaluation and future clinical trials are all discussed in detail.

Our PHPN article for this issue discusses the care of the infant with bronchopulmonary dysplasia and PH. Claire Parker, Natalie Villafranco, Nidhy Varghese and Elise Whalen give us a thorough overview of the comprehensive approach to care with consideration for multiple organ systems and with an interdisciplinary team of experts for these infants.

And lastly, but certainly not least, Dr. Jeff Edelman leads an extraordinary round table on the conundrums and controversies in PH-ILD discussing when and how to treat patients. The roundtable included world-class experts discussing their experience, opinions and the published literature on this topic. I would like to thank Drs. Jean Elwing, MD, Anjali Vaidya, MD and Steve Mathai, MD, for this up to date and incredibly important discussion.

Thank you to all of the authors, and everyone at PHA and Allen Press who have worked so hard to bring this outstanding issue to all of us.

Thank you again for joining us for this issue.